1. Home
  2. RMCF vs ALLR Comparison

RMCF vs ALLR Comparison

Compare RMCF & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$1.68

Market Cap

27.2M

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

26.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
ALLR
Founded
1981
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
26.1M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
RMCF
ALLR
Price
$1.68
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
38.4K
243.6K
Earning Date
06-16-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$0.77
52 Week High
$2.99
$2.35

Technical Indicators

Market Signals
Indicator
RMCF
ALLR
Relative Strength Index (RSI) 29.64 54.01
Support Level $1.48 $1.34
Resistance Level $1.82 $1.80
Average True Range (ATR) 0.13 0.16
MACD -0.04 -0.01
Stochastic Oscillator 11.23 54.22

Price Performance

Historical Comparison
RMCF
ALLR

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: